Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) are an allogeneic cell therapy developed by A.O. Ospedale Papa Giovanni XXIII for the treatment of severe, steroid-resistant acute graft-versus-host disease (GvHD). These multipotent cells possess potent immunomodulatory properties, functioning by suppressing the activation and proliferation of various immune effector cells, such as T cells and natural killer cells, while promoting the activity of regulatory T cells. In clinical development, these cells are being evaluated for their safety and efficacy when administered intravenously, often as part of a sequential treatment regimen following other immunosuppressive agents like pentostatin, to manage the systemic inflammatory response in patients who have failed first-line corticosteroid therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Umbilical cord-derived mesenchymal stromal cells (A.O. Ospedale Papa Giovanni XXIII).